<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1851">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05137067</url>
  </required_header>
  <id_info>
    <org_study_id>RPC006</org_study_id>
    <nct_id>NCT05137067</nct_id>
  </id_info>
  <brief_title>A Novel Approach for Alleviating the Side Effects of Chemotherapeutic Agents.</brief_title>
  <official_title>Effectiveness of RaproCell in Alleviating the Side Effects of Chemotherapeutic Agents, Without Adversely Impacting the Overall Success of the Agents on Cancer Cells.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Optimal Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Optimal Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the effectiveness of a natural nutraceutical in treating the known&#xD;
      side effects of chemotherapeutic agents in cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will assess the effectiveness of a natural nutraceutical in treating the known&#xD;
      side effects of chemotherapeutic agents in cancer patients. The study will be observing the&#xD;
      standard treatment protocol for any degradation or enhancement due to the nutraceutical.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2021</start_date>
  <completion_date type="Anticipated">January 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized interventional parallel study</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Active product and placebo will be in identical packets.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>PROMIS (Patient-Reported Outcomes Measurement Information System) Global 10 Health Questionnaire to assess change from baseline.</measure>
    <time_frame>Once a week for 3 months</time_frame>
    <description>A summary indicator of health status by assessing 5 domains: physical function, fatigue, pain, emotional distress, and social health to assess change from baseline for improvement or decline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptom Assessment Questionnaire to assess change from baseline.</measure>
    <time_frame>Once a week for 3 months</time_frame>
    <description>A symptom is a sensation or perception of change related to health function experienced by an individual. Symptoms such as fatigue, pain and nausea can be classified according to their severity and perceived impact on function as a change from baseline for improvement or decline.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cancer antigens blood markers to assess change from baseline.</measure>
    <time_frame>Once a week for 3 months.</time_frame>
    <description>Breast: CA 27.29, serial monitor report; carcinoembryonic antigen (CEA), serial monitor report; lipid-associated sialic acid (LASA), serial monitor report. Lung: Carcinoembryonic antigen (CEA), serial monitor report; lipid-associated sialic acid (LASA), serial monitor report; neuron-specific enolase (NSE), serial monitor report. Prostate: Prostate-specific antigen (PSA), serial monitor report; prostatic acid phosphatase (PAP), serial monitor report as a change from baseline for improvement or decline.</description>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Lung Cancer</condition>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent A (Docetaxel)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients with breast cancer will receive chemotherapeutic agent A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent A (Docetaxel) plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients with breast cancer will receive chemotherapeutic agent A plus a placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent A (Docetaxel) plus RaproCell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with breast cancer will receive chemotherapeutic agent A plus RaproCell.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent B (Cisplatin)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients with lung cancer will receive Chemotherapeutic agent B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent B (Cisplatin) plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients with lung cancer will receive Chemotherapeutic agent B plus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent B (Cisplatin) plus RaproCell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with lung cancer will receive Chemotherapeutic agent B plus RaproCell.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent C (Docetaxel)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The patients with prostate cancer will receive Chemotherapeutic agent C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent C (Docetaxel) plus placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients with prostate cancer will receive Chemotherapeutic agent C plus placebo.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapeutic agent C plus (Docetaxel) RaproCell</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The patients with prostate cancer will receive Chemotherapeutic agent C plus RaproCell.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus Dietary Supplement (RaproCell)</intervention_name>
    <description>Chemotherapeutic side effect elimination without adversely effecting the Chemotherapeutic agent drug.</description>
    <arm_group_label>Chemotherapeutic agent A (Docetaxel) plus RaproCell</arm_group_label>
    <arm_group_label>Chemotherapeutic agent B (Cisplatin) plus RaproCell</arm_group_label>
    <arm_group_label>Chemotherapeutic agent C plus (Docetaxel) RaproCell</arm_group_label>
    <other_name>RaproCell</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel) plus placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Chemotherapeutic agent A (Docetaxel) plus placebo</arm_group_label>
    <arm_group_label>Chemotherapeutic agent B (Cisplatin) plus placebo</arm_group_label>
    <arm_group_label>Chemotherapeutic agent C (Docetaxel) plus placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).</intervention_name>
    <description>Chemotherapeutic agent A(Docetaxel),B(Cisplatin) or C(Docetaxel).</description>
    <arm_group_label>Chemotherapeutic agent A (Docetaxel)</arm_group_label>
    <arm_group_label>Chemotherapeutic agent B (Cisplatin)</arm_group_label>
    <arm_group_label>Chemotherapeutic agent C (Docetaxel)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Active breast cancer patients taking one of the studies listed drugs within the age range.&#xD;
&#xD;
        Active lung cancer patients taking one of the studies listed drugs within the age range.&#xD;
&#xD;
        Active prostate cancer patients taking one of the studies listed drugs within the age&#xD;
        range.&#xD;
&#xD;
        -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Anyone without the three types of cancer (breast cancer, lung cancer, prostate cancer)&#xD;
        listed in inclusion criteria.&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Breast cancer: Female only&#xD;
Lung cancer: Both Female and Male&#xD;
Prostate cancer: Male</gender_description>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>EA Jeppsen, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Optimal Health Clinic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Optimal Health Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 11, 2021</study_first_submitted>
  <study_first_submitted_qc>November 23, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 30, 2021</study_first_posted>
  <last_update_submitted>November 29, 2021</last_update_submitted>
  <last_update_submitted_qc>November 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Breast Lung Prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Antineoplastic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

